zevalin

McNicoll Lewis Vlak has published a research report on Spectrum Pharmaceuticals (NASDAQ: SPPI) after the company reported positive results from Zevalin in the Journal 'Cancer'. In the report, MLV writes, "In several studies, we think Zevalin is beginning to demonstrate its potential for wide...

Auriga has published a research on Spectrum Pharmaceuticals (NASDAQ: SPPI) and has raised the price target on on the company to $15. In the report, Auriga writes, "Spectrum Pharmaceuticals receives the FDA's approval for the removal of the bioscan requirement of Zevalin. It not only simplifies the...